By Michael Erman and Deena Beasley Jan 27 (Reuters) - The U.S. government on Tuesday named the 15 new drugs targeted for ...
Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA ...
The FDA has accepted Otsuka’s New Drug Application for centanafadine, a first-in-class norepinephrine, dopamine and serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit ...
The FDA has approved a label update for an inhaled insulin indicated for adults with type 1 or type 2 diabetes, according to ...
The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...
The proposed rescheduling of marijuana could have far-reaching implications in science, medicine and criminal justice. What ...
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor designed to address the core symptoms of ADHD in children and adults.
The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...
The Supreme Court on Jan. 16, 2026, agreed to decide a case about how generic companies can communicate to the market about their products, ...
Migraine Again on MSN
Nurtec ODT: FDA approved as the only migraine medication for prevention and acute treatment
Discover how rimegepant (Nurtec ODT) works for both migraine treatment and prevention. Learn about the approved age range, dosage, and how long it takes to see results.
The presbyopia space gained another player as Tenpoint Therapeutics Ltd. won the U.S. FDA’s go-ahead for Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution, 2.75%/0.1%, previously known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results